EF-2001 lactic acid bacteria are Enterococcus faecalis EF-2001 and are patented by BeRM co., Ltd. There are many kinds of lactic acid bacteria. Research has shown that EF-2001 lactic acid bacteria have the significantly higher immune activation capacity compared to Lactobacillus and Bifidum in yoghurt.
Based on this feature, BRM Group obtained a patent for EF-2001 lactic acid bacteria in 2001 as a Biological Response Modifier. Also, the quality is excellent because they carry out the immune activation test at every production process with OK432(PICIBANIL), a immunomodulatory drug and release only accepted products
Our high-dosage concentration technic and EF-2001 strain selection enabled production of 7.5 trillion probiotics: the highest probiotic concentration in the world (Normal Commercial Probiotics number range from 1~100 billion cfu). Considering these factors, our Heat-killed probiotics are apt for Functional & Pharmaceutical use.
Two factors determine the quality of probiotics: The type of strain and concentration technology. Strains that have a higher immune activation capacity result in a more balanced immune system. Probiotics produced with advanced concentration technology are able to reach increased contact rates to biological receptors which helps maintains homeostasis(healthy state). EF-2001 satisfies both qualities resulting in a high quality probiotics end product.
According to Weizmann Institute of Science, there are around 30~40 trillion microorganisms building up our gut microbiota whereas the number of M cells (the cell that activates mucosal immunity) are limited around 30~40 in 8m of small intestine. Higher contact rate as possible of probiotics with these M cells is essential for M cell immune mechanism. Therefore, high-dosage is vital for immune activation.